Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in...
Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switz...
19 Dec 2019
Prognostic impact of chromosomal abnormalities and copy number alterations in B-...
Prof Anthony Moorman - Newcastle University, Newcastle, UK
19 Dec 2019
Long-term outcomes of subjects with EBV driven PTLD following solid organ or all...
Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA
19 Dec 2019
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT afte...
Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA
19 Dec 2019
Outcomes in patients with therapy-Related AML who achieved remission with CPX-35...
Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, US...
19 Dec 2019
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML tr...
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
18 Dec 2019
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
18 Dec 2019
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from ...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
18 Dec 2019
LYRA: Maintenance therapy with daratumumab improves depth of response and achiev...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
17 Dec 2019
KRd consolidation in MM patients with a positive PET-CT after standard first-lin...
Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway
17 Dec 2019
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzu...
Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene...
17 Dec 2019
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell l...
Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA
17 Dec 2019
